Senate Finance Committee chair demands answers on 'reprehensible' Zolgensma 'data manipulation'
If the accusation of withholding information over Zolgensma (onasemnogene abeparvovec-xioi) is the first major test for Novartis chief executive Vasant Narasimhan (pictured above), then it is increasingly looking like a big one.
Senate Finance Committee chairman Chuck Grassley is the latest US politician to demand answers from Dr Narasimhan on what happened with the gene therapy, which was approved by the US Food and Drug Administration (FDA) on May 24 to treat children of less than two years of age with spinal muscular atrophy (SMA).
Product remains on market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze